Tag: Regulatory

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PepGen To Contact Him Directly To Discuss Their Options

Award Recognition underscores the importance of AI-driven drug discovery

Mercado Libre now holds investment grade ratings from two leading agencies with S&P following Fitech's upgrade in October 2024

BOCA RATON, FL, July 11, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced the signing of a non-binding Letter of Intent (LOI) with Switchboard Technology Labs Inc., a core contributor to the Switchboard Protocol, a leading decentralized oracle network on Solana.

HOUSTON, TX, July 11, 2025 (GLOBE NEWSWIRE) -- Houston American Energy Corp. (NYSE American: HUSA) (“HUSA” or the “Company”) today announced it has secured a Common Stock Purchase Agreement with an institutional investor, establishing an equity line of credit of up to $100 million. The Company intends to use the proceeds to accelerate its growth strategy, including strategic acquisitions, scaling operations, and expanding its presence in the low-carbon fuels and chemicals sector.

Proceeds to Fund Portion of Acquisition of 25-Acre Location at Cedar Port Industrial Park, Future Site of Plastics-to-Low-Carbon Fuels Hub

New additions bolster Hapbee as it scales product reach, tech pipeline, and international presence.

SOUTH SAN FRANCISCO, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 2,100 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on July 8, 2025 (the “Grant Date”), in connection with the commencement of employment.

Exhale Wellnes was recently ranked No.1 THCA flower brand by industry peers. Read more about its product line, bestsellers, and why it stood out. 

PHILADELPHIA and VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced updated Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, in combination with an immune check point inhibitor (CPI).